These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36322904)

  • 21. Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.
    Radtke KP; Griffin JH; Riceberg J; Gale AJ
    J Thromb Haemost; 2007 Jan; 5(1):102-8. PubMed ID: 17059431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation.
    Brophy DF; Martin EJ; Ninivaggi M; Mohammed BM; Barrett JC; Kuhn J; Nolte ME; Waters EK; Ezban M
    Haemophilia; 2018 Sep; 24(5):815-822. PubMed ID: 30112856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.
    Damon AL; Scudder LE; Gnatenko DV; Sitaraman V; Hearing P; Jesty J; Bahou WF
    Thromb Haemost; 2008 Dec; 100(6):1111-22. PubMed ID: 19132238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase.
    Jenkins PV; Dill JL; Zhou Q; Fay PJ
    Biochemistry; 2004 May; 43(17):5094-101. PubMed ID: 15109268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.
    Kamikubo Y; Mendolicchio GL; Zampolli A; Marchese P; Rothmeier AS; Orje JN; Gale AJ; Krishnaswamy S; Gruber A; Østergaard H; Petersen LC; Ruf W; Ruggeri ZM
    Blood; 2017 Oct; 130(14):1661-1670. PubMed ID: 28729433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies.
    Matsumoto T; Nogami K; Ogiwara K; Shima M
    Thromb Haemost; 2012 Feb; 107(2):288-301. PubMed ID: 22234708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activated protein C has a regulatory role in factor VIII function.
    Wilhelm AR; Parsons NA; Samelson-Jones BJ; Davidson RJ; Esmon CT; Camire RM; George LA
    Blood; 2021 May; 137(18):2532-2543. PubMed ID: 33512448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.
    Yada K; Nogami K; Wakabayashi H; Fay PJ; Shima M
    Thromb Haemost; 2013 Jun; 109(6):1007-15. PubMed ID: 23467620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unique surface-exposed hydrophobic residues in the C1 domain of factor VIII contribute to cofactor function and von Willebrand factor binding.
    Przeradzka MA; Freato N; Boon-Spijker M; van Galen J; van der Zwaan C; Mertens K; van den Biggelaar M; Meijer AB
    J Thromb Haemost; 2020 Feb; 18(2):364-372. PubMed ID: 31675465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII.
    Bovenschen N; Boertjes RC; van Stempvoort G; Voorberg J; Lenting PJ; Meijer AB; Mertens K
    J Biol Chem; 2003 Mar; 278(11):9370-7. PubMed ID: 12522143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets.
    Saenko EL; Scandella D; Yakhyaev AV; Greco NJ
    J Biol Chem; 1998 Oct; 273(43):27918-26. PubMed ID: 9774404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Na+ site in blood coagulation factor IXa: effect on catalysis and factor VIIIa binding.
    Schmidt AE; Stewart JE; Mathur A; Krishnaswamy S; Bajaj SP
    J Mol Biol; 2005 Jul; 350(1):78-91. PubMed ID: 15913649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a novel flow chamber system to assess clot formation in factor VIII-deficient mouse and anti-factor IXa-treated human blood.
    Ogawa S; Szlam F; Dunn AL; Bolliger D; Ohnishi T; Hosokawa K; Tanaka KA
    Haemophilia; 2012 Nov; 18(6):926-32. PubMed ID: 22642581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux.
    Szlam F; Sreeram G; Solomon C; Levy JH; Molinaro RJ; Tanaka KA
    Thromb Res; 2011 Feb; 127(2):135-40. PubMed ID: 21144556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex.
    Kerschbaumer RJ; Riedrich K; Kral M; Varadi K; Dorner F; Rosing J; Scheiflinger F
    J Biol Chem; 2004 Sep; 279(39):40445-50. PubMed ID: 15265864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Binding studies of the enzyme (factor IXa) with the cofactor (factor VIIIa) in the assembly of factor-X activating complex on the activated platelet surface.
    Ahmad SS; London FS; Walsh PN
    J Thromb Haemost; 2003 Nov; 1(11):2348-55. PubMed ID: 14629468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice.
    Østergaard H; Lund J; Greisen PJ; Kjellev S; Henriksen A; Lorenzen N; Johansson E; Røder G; Rasch MG; Johnsen LB; Egebjerg T; Lund S; Rahbek-Nielsen H; Gandhi PS; Lamberth K; Loftager M; Andersen LM; Bonde AC; Stavenuiter F; Madsen DE; Li X; Holm TL; Ley CD; Thygesen P; Zhu H; Zhou R; Thorn K; Yang Z; Hermit MB; Bjelke JR; Hansen BG; Hilden I
    Blood; 2021 Oct; 138(14):1258-1268. PubMed ID: 34077951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isolation and characterization of thrombin-activated human factor VIII.
    Curtis JE; Helgerson SL; Parker ET; Lollar P
    J Biol Chem; 1994 Feb; 269(8):6246-51. PubMed ID: 8119969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa.
    Pipe SW; Kaufman RJ
    Proc Natl Acad Sci U S A; 1997 Oct; 94(22):11851-6. PubMed ID: 9342326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterisation of an antibody specific for coagulation factor VIII that enhances factor VIII activity.
    Takeyama M; Nogami K; Matsumoto T; Soeda T; Suzuki T; Hattori K; Shima M
    Thromb Haemost; 2010 Jan; 103(1):94-102. PubMed ID: 20062922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.